ArticleCancer medicine2021

CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.

Masahiro Nishikawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.